Suppr超能文献

工业化国家和发展中国家耐抗生素淋病奈瑟菌的流行病学

Epidemiology of antibiotic resistant Neisseria gonorrhoeae in industrialized and developing countries.

作者信息

Lind I

机构信息

Neisseria Department, Statens Seruminstitut, Copenhagen S, Denmark.

出版信息

Scand J Infect Dis Suppl. 1990;69:77-82.

PMID:2124728
Abstract

The in vitro susceptibility of Neisseria gonorrhoeae to antimicrobial drugs has been studied currently for around fifty years, and it has been convincingly demonstrated that the results of the in vitro determinations can be used as a guideline for choice of an efficient standard treatment regimen as well as for the choice of therapeutic agent in individual cases. During these past 50 years, the susceptibility of gonococci to antimicrobial drugs has undergone dramatic changes. The genetic background is chromosomal mutations as well as the acquisition of R plasmids. The selective pressure has been exerted both by use (and misuse) of antibiotics in treatment of patients and by factors in the micro-environment of the gonococcus. Review of the current spectrum of antimicrobial susceptibility patterns of N. gonorrhoeae in industrialized and developing countries and a comparison with the changing epidemiology of gonorrhoea, rises the question as to what extent antimicrobial resistance and the choice of treatment regimen influence the spread of gonorrhoea (and other sexually transmitted diseases). In the developed countries, in spite of the access to an optimal antibiotic treatment, the prevalence of gonorrhoea increased significantly in the beginning of the 1970s and remained at a high level until around 1985. Then--within the following subsequent few years--the gonorrhoea rate fell dramatically e.g. in Scandinavia. This fall coincides with the establishment of comprehensive educational programmes for the promotion of changes in sexual lifestyle. It is therefore tempting to conclude that the impact of increasing antimicrobial resistance on the changing epidemiology of gonorrhoea is minor.

摘要

淋病奈瑟菌对抗菌药物的体外敏感性已被研究了约五十年,令人信服的是,体外测定结果可作为选择有效标准治疗方案以及个别病例中治疗药物选择的指导。在过去的五十年中,淋球菌对抗菌药物的敏感性发生了巨大变化。其遗传背景是染色体突变以及R质粒的获得。选择性压力既来自患者治疗中抗生素的使用(和滥用),也来自淋球菌微环境中的因素。回顾工业化国家和发展中国家淋病奈瑟菌当前的抗菌药敏谱,并与淋病不断变化的流行病学进行比较,引发了一个问题,即抗菌药物耐药性和治疗方案的选择在多大程度上影响淋病(以及其他性传播疾病)的传播。在发达国家,尽管有最佳的抗生素治疗,但淋病患病率在20世纪70年代初显著上升,并一直保持在较高水平直到1985年左右。然后,在随后的几年里,淋病发病率急剧下降,例如在斯堪的纳维亚半岛。这种下降与为促进性生活方式改变而开展的全面教育计划的建立相吻合。因此,很容易得出结论,抗菌药物耐药性增加对淋病不断变化的流行病学的影响很小。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验